vs

Side-by-side financial comparison of Dingdong (Cayman) Ltd (DDL) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

Dingdong (Cayman) Ltd is the larger business by last-quarter revenue ($115.3M vs $60.1M, roughly 1.9× RHYTHM PHARMACEUTICALS, INC.). Dingdong (Cayman) Ltd runs the higher net margin — 5.8% vs -92.6%, a 98.4% gap on every dollar of revenue.

Dingdong (Cayman) Ltd operates a leading on-demand grocery e-commerce platform primarily serving the Chinese market. It provides fresh produce, daily necessities, ready-to-eat meals, and household staples to urban consumers, leveraging optimized supply chains and localized logistics networks to offer fast, reliable 30-minute delivery services, prioritizing product freshness and user convenience.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

DDL vs RYTM — Head-to-Head

Bigger by revenue
DDL
DDL
1.9× larger
DDL
$115.3M
$60.1M
RYTM
Higher net margin
DDL
DDL
98.4% more per $
DDL
5.8%
-92.6%
RYTM

Income Statement — Q3 FY2022 vs Q1 FY2026

Metric
DDL
DDL
RYTM
RYTM
Revenue
$115.3M
$60.1M
Net Profit
$6.7M
$-55.6M
Gross Margin
88.1%
Operating Margin
5.3%
-87.1%
Net Margin
5.8%
-92.6%
Revenue YoY
83.8%
Net Profit YoY
EPS (diluted)
$-0.02
$-0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DDL
DDL
RYTM
RYTM
Q1 26
$60.1M
Q4 25
$57.3M
Q3 25
$51.3M
Q2 25
$48.5M
Q1 25
$32.7M
Q4 24
$41.8M
Q3 24
$33.3M
Q2 24
$29.1M
Net Profit
DDL
DDL
RYTM
RYTM
Q1 26
$-55.6M
Q4 25
$-47.5M
Q3 25
$-52.9M
Q2 25
$-46.6M
Q1 25
$-49.5M
Q4 24
$-43.3M
Q3 24
$-43.6M
Q2 24
$-32.3M
Gross Margin
DDL
DDL
RYTM
RYTM
Q1 26
88.1%
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Operating Margin
DDL
DDL
RYTM
RYTM
Q1 26
-87.1%
Q4 25
-82.2%
Q3 25
-102.6%
Q2 25
-93.4%
Q1 25
-143.7%
Q4 24
-98.6%
Q3 24
-132.0%
Q2 24
-139.2%
Net Margin
DDL
DDL
RYTM
RYTM
Q1 26
-92.6%
Q4 25
-83.0%
Q3 25
-103.1%
Q2 25
-96.1%
Q1 25
-151.4%
Q4 24
-103.6%
Q3 24
-131.2%
Q2 24
-110.9%
EPS (diluted)
DDL
DDL
RYTM
RYTM
Q1 26
$-0.83
Q4 25
$-0.73
Q3 25
$-0.82
Q2 25
$-0.75
Q1 25
$-0.81
Q4 24
$-0.71
Q3 24
$-0.73
Q2 24
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DDL
DDL
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$113.7M
$340.6M
Total DebtLower is stronger
$135.8K
Stockholders' EquityBook value
$4.5M
$122.9M
Total Assets
$178.3M
$442.3M
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DDL
DDL
RYTM
RYTM
Q1 26
$340.6M
Q4 25
$388.9M
Q3 25
$416.1M
Q2 25
$291.0M
Q1 25
$314.5M
Q4 24
$320.6M
Q3 24
$298.4M
Q2 24
$319.1M
Stockholders' Equity
DDL
DDL
RYTM
RYTM
Q1 26
$122.9M
Q4 25
$139.1M
Q3 25
$148.8M
Q2 25
$-11.9M
Q1 25
$18.9M
Q4 24
$21.7M
Q3 24
$11.2M
Q2 24
$39.3M
Total Assets
DDL
DDL
RYTM
RYTM
Q1 26
$442.3M
Q4 25
$480.2M
Q3 25
$506.9M
Q2 25
$372.7M
Q1 25
$386.7M
Q4 24
$392.3M
Q3 24
$363.6M
Q2 24
$381.8M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons